# Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

> **NCT02530437** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma
- Stage IB Esophageal Adenocarcinoma AJCC v7
- Stage II Esophageal Adenocarcinoma AJCC v7
- Stage IIA Esophageal Adenocarcinoma AJCC v7
- Stage IIB Esophageal Adenocarcinoma AJCC v7
- Stage IIIA Esophageal Adenocarcinoma AJCC v7
- Stage IIIB Esophageal Adenocarcinoma AJCC v7

## Interventions

- **DRUG:** Carboplatin
- **RADIATION:** External Beam Radiation Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **DRUG:** Taladegib

## Key facts

- **NCT ID:** NCT02530437
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-07
- **Primary completion:** 2022-01-07
- **Final completion:** 2022-01-07
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was available. The sponsor made a decision to stop development of this drug Taladegib.
- **Last updated:** 2023-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02530437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02530437, "Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02530437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*